News

WASHINGTON, D.C.  – Today, Congressman Brett Guthrie (KY-02), Chairman of the House Committee on Energy and Commerce, Congressman Gus Bilirakis (FL-12), Chairman of the Subcommittee on Commerce, Manufacturing, and Trade, and Congressman Gary Palmer (AL-06), Chairman of the Subcommittee on Oversight and Investigations, sent a letter to 23andMe regarding the handling of Americans' sensitive data following the company's decision to file for bankruptcy. KEY EXCERPT: “According to 23andMe’s privacy statement, in a bankruptcy, customers’ ‘Personal Information may be accessed, sold or transferred as part of that transaction and this Privacy Statement will apply to [customer] Personal Information as transferred to the new entity.’ Additionally, a judge recently ruled 23andMe has the right to sell the sensitive medical and genetic information of its 15 million customers, which is considered to be the company’s most valuable asset. With the lack of a federal comprehensive data privacy and security law, we write to express our great concern about the safety of Americans’ most sensitive personal information.” Background: On March 23, 2025, 23andMe initiated Chapter 11 bankruptcy proceedings, which could have ramifications for the highly sensitive information of millions of Americans. While Americans’ personal health information is protected under the Health Insurance Portability and Accountability Act (HIPAA), these protections only apply if the information is collected by a HIPAA covered entity. Generally, direct-to-consumer companies, like 23andMe, are not covered by HIPAA. Customers have reported issues accessing and deleting their data from their 23andMe accounts. The Chairmen have requested answers to the following questions: If 23andMe were to sell the personal information of its customers either as a standalone asset or as part of a broader sale of the company, what post-sale data privacy and security protections would be in place for its customers’ personal information? Please describe how the representations made in 23andMe’s privacy statement will continue to apply—and be enforced—if the personal information of 23andMe’s customers is sold to a third party. Please include in this response information about what, if anything, would hold a third-party buyer to 23andMe’s privacy statement or prevent it from subsequently using, transferring, or otherwise selling, such information in the future. Does 23andMe plan to change its privacy statement at any time prior to selling any customers’ personal information? If so, please explain the change 23andMe plans to implement and when those changes will go into effect. Does 23andMe intend to vet prospective buyers to which it may sell its customers’ personal information? If so, please detail the vetting process and whether it will include the prospective buyer’s history of implementing data security protections and compliance with sectoral, state, or any other data privacy and security laws. If not, please explain why. Please detail the categories of customer information 23andMe has, and of that what 23andMe is considering selling. Has 23andMe notified its customers of the company’s bankruptcy announcement? If so, please attach the customer notification. If not, please explain why. Has 23andMe provided its customers with a guide for how to delete, or request to delete any information currently in 23andMe’s possession? If so, please provide a copy of that guide and specify when it was provided to customers. If not, please explain why, and explain whether 23andMe will contact each of its customers and provide an opportunity to delete their personal information prior to a potential sale of the company or personal information maintained by the company. Please detail the number of requests 23andMe received from its customers to delete their personal information between when 23andMe filed for bankruptcy and the date of the response to this letter. Of those requests, please provide a breakdown of how many requests were made by customers through their 23andMe online accounts and how many were made via customer service calls because customers were unable to successfully delete their information through their online accounts. Of those requests, please detail the number of fulfilled requests. Will 23andMe offer for sale any information in which a customer has requested the deletion of such information? If so, does 23andMe’s privacy policy consider selling information a legitimate purpose for retaining information past a customer's request to delete their information? Will 23andMe deidentify its customers’ personal information prior to selling it or the company? If so, please detail which information will be deidentified. If not, please explain why the company is electing not to deidentify information. CLICK HERE to read the full letter. CLICK HERE to read the story from CNBC. ###

WASHINGTON, D.C. – Last week, Congressman Brett Guthrie (KY-02), Chairman of the House Committee on Energy and Commerce, Congressman Gary Palmer (AL-06), Chairman of the Subcommittee on Oversight and Investigations, and Congressman Morgan Griffith (VA-09), Chairman of the Subcommittee on Environment, wrote letters to eight Greenhouse Gas Reduction Fund (GGRF) grant recipients. In Case You Missed It: “SCOOP: Biden-era grant program described as ‘gold bar’ scheme by Trump EPA administrator under scrutiny” Fox News Alec Schemmel April 11, 2025 Republicans in Congress are launching a probe into a Biden-era green energy grant program that sent billions in funding to climate groups tied to Democrats and former President Joe Biden’s allies. GOP leaders on the House Energy and Commerce Committee sent letters to the eight nonprofits awarded grants from the $20 billion Greenhouse Gas Reduction Fund (GGRF), seeking answers to ensure the Biden Environmental Protection Agency (EPA) followed proper ethics and conflict of interest protocols in distributing the funds. In February, the Trump administration’s EPA announced it would take steps to get the money back, citing concerns over a lack of oversight related to how the money was being disbursed. In the announcement, new EPA administrator Lee Zeldin cited comments from a former Biden EPA political appointee, who described disbursements made through GGRF as akin to “tossing gold bars off the Titanic,” because Biden officials were allegedly trying to get money out the door before Trump took over. It was also revealed that $2 billion from GGRF went to a Stacy Abrams-linked group, Power Forward Communities, which had not been established until after the Biden administration announced the GGRF application process. Meanwhile, during Power Forward’s first few months of operations – prior to receiving the funding – the group reported just $100 in revenue. Climate United, another group that received the most money from the GGRF, roughly $7 billion, currently staffs a former Biden climate advisor who worked during the last two years of the former president’s term. The same group is also run by a CEO with ties to the Obama administration and a board member who was among those invited to Biden’s signing ceremony for his multitrillion-dollar infrastructure bill in 2021.  Several GGRF grant recipients have ties to Democrats and Biden advisors, and some were reportedly founded shortly before or after the Biden administration announced the program. Meanwhile, these groups, according to Zeldin, had sole discretion on how to use the funds. House Energy and Commerce Chairman Brett Guthrie, R-Ky., alongside fellow committee members Reps. Gary Palmer of Alabama and Morgan Griffith of Virginia, both Republicans, said in a joint statement that their investigation into the GGRF recipients will be “key” to understanding whether these funds were allocated “fairly and impartially to qualified applicants,” while also helping to determine the manner in which the money has been used. “The Committee has had concerns about the Greenhouse Gas Reduction Fund program since its creation—including concerns about the program’s unusual structure, a potential lack of due diligence in selecting award recipients, and the recipients’ ability to manage the large influx of federal dollars they received from the EPA,” the lawmakers said in their statement. “A recent Oversight and Investigations Subcommittee hearing that examined these concerns coupled with the speed with which money was pushed out the door by the Biden Administration’s EPA heightened the Committee’s concerns and raised additional questions about certain Greenhouse Gas Reduction Fund recipients.”  Several of the groups that were recipients of GGRF money sued the Trump administration in March over its attempts to rake back the funds.  Subsequently, Obama-appointed Judge Tanya Chutkan issued a temporary restraining order preventing the EPA from freezing $14 billion in GGRF funds awarded to three of the climate groups.  Background: The Inflation Reduction Act (IRA) authorized the Environmental Protection Agency (EPA) to create and implement a $27 billion GGRF program. Of this appropriation, $20 billion was awarded to just eight grant recipients; with $14 billion awarded to three grant recipients under the National Clean Investment Fund (NCIF) program and $6 billion awarded to five grant recipients under the Clean Communities Investment Accelerator (CCIA) program.   Letters:  National Clean Investment Fund Program Recipients Coalition for Green Capital Climate United Fund Power Forward Communities   Clean Communities Investment Accelerator Program Recipients Justice Climate Fund Opportunity Finance Network Inclusiv Native CDFI Network Appalachian Community Capital ###

WASHINGTON, D.C. – This week, Congressman Brett Guthrie (KY-02), Chairman of the House Committee on Energy and Commerce, Congressman Gary Palmer (AL-06), Chairman of the Subcommittee on Oversight and Investigations, and Congressman Morgan Griffith (VA-09), Chairman of the Subcommittee on Environment, wrote letters to eight Greenhouse Gas Reduction Fund (GGRF) grant recipients. “The Committee has had concerns about the GGRF program—including the program’s unusual structure and a potential lack of due diligence in selecting award recipients. A recent Oversight and Investigations Subcommittee hearing examined these issues and the speed with which money was pushed out the door by the Biden Administration’s EPA, which raised additional questions about certain GGRF recipients.” said Chairmen Guthrie, Palmer, and Griffith. “ This investigation is key to evaluating whether these funds were awarded fairly and impartially to qualified applicants and determining how the federal funds are being used.” Background:  The Inflation Reduction Act (IRA) authorized the Environmental Protection Agency (EPA) to create and implement a $27 billion GGRF program. Of this appropriation, $20 billion was awarded to just eight grant recipients; with $14 billion awarded to three grant recipients under the National Clean Investment Fund (NCIF) program and $6 billion awarded to five grant recipients under the Clean Communities Investment Accelerator (CCIA) program.    Letters: National Clean Investment Fund Program Recipients Coalition for Green Capital Climate United Fund Power Forward Communities   Clean Communities Investment Accelerator Program Recipients Justice Climate Fund Opportunity Finance Network Inclusiv Native CDFI Network Appalachian Community Capital Read the story here . ###

Washington, D.C. — In a new letter to Department of Health and Human Services (HHS) Inspector General Christi Grimm, House Energy and Commerce Committee Republicans requested an investigation into the strength, quality, and types of evidence-based scientific and pediatric medical literature relied on by the department to promote gender transition procedures for children.  KEY LETTER EXCERPT:  “As the agency responsible for safeguarding the health and well-being of Americans, all of HHS’s medical treatment recommendations, especially medical treatment recommendations for children, should be based on rigorous and well-established research, such as randomized controlled trials, that have definitively illustrated the long-term benefits of gender affirming care treatments.”  BACKGROUND:  Under the Biden administration, HHS has advocated for sex reassignment procedures on minors, including the use of serum puberty blockers, which have historically been used to treat children with precocious puberty (i.e., early onset puberty affecting about one percent of U.S. children) and sex offenders.   Puberty blockers, however, are known to stunt normal childhood development in children unaffected by precocious puberty.  HHS officials contend that sex reassignment procedures on minors are an unanimously accepted medical practice.  HHS Secretary Becerra testified before Congress that “every major medical association,” “medical journals,” and “scientific and medical evidence” has demonstrated the benefits of transitioning children’s biological sex.  When asked, via a Freedom of Information Act request, for the underlying scientific or medical basis for its position, HHS was only able to produce a two-page brochure that was already publicly available.  In contrast to HHS, a growing body of literature from medical experts and authorities around the world, including those in Europe, caution against performing such procedures on minors.   Courts and government health agencies responsible for determining child welfare have sought to limit child sex reassignment procedures.   Other countries have banned these interventions and surgeries on minors altogether.  An article published in the British Journal of Medicine found “there is great uncertainty about the effects of puberty blockers, cross-sex hormones, and surgeries in young people.”   A court in the United Kingdom noted the obvious about administering puberty blocking chemicals onto children: “[i]t is highly unlikely that a child aged 13 or under would be competent to give consent to the administration of puberty blockers. It is doubtful that a child aged 14 or 15 could understand and weigh the long-term risks and consequences of the administration of puberty blockers.”  In April 2024, the Cass Review , an independent review of gender identity services for children and young people, commissioned by the National Health Service England, found “[w]hile a considerable amount of research has been published in this field, systematic evidence reviews demonstrated the poor quality of the published studies, meaning there is not a reliable evidence base upon which to make clinical decisions, or for children and their families to make informed choices.”   The Cass Review also found that “[t]he rationale for early puberty suppression remains unclear, with weak evidence regarding the impact on gender dysphoria, mental or psychosocial health,” as well as unknown effects on cognitive and psychosexual development.  In August 2024, the American Society of Plastic Surgeons (ASPS) became the first major U.S. medical association to express caution on the use of gender surgery for gender dysphoria in adolescents. In its formal statement, the association stated: “ASPS currently understands that there is considerable uncertainty as to the long-term efficacy for the use of chest and genital surgical interventions for the treatment of adolescents with gender dysphoria, and the existing evidence base is viewed as low quality/low certainty. This patient population requires specific considerations.”   The letter was signed by Committee Chair Cathy McMorris Rodgers (R-WA), Subcommittee on Health Chair Brett Guthrie (R-KY), Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA), Rep. Dan Crenshaw (R-TX), Rep. Gus Bilirakis (R-FL), Rep. Buddy Carter (R-GA), Rep. Gary Palmer (R-AL), Rep. Neal Dunn (R-FL), Rep. Randy Weber (R-TX), Rep. Troy Balderson (R-OH), Rep. August Pfluger (R-TX), Rep. Diana Harshbarger (R-TN), and Rep. Kat Cammack (R-FL).  CLICK HERE to read the letter.

House Republicans scrutinize government grant funding recipients that fail to protect individuals from antisemitism Washington, D.C. — In a new letter to J. David Gladstone Institutes President Dr. Deepak Srivastava, the House Committee on Energy and Commerce (E&C) and House Committee on Education and the Workforce (E&W) have requested information about ongoing and pervasive acts of antisemitic harassment and intimidation at Gladstone and its leadership’s insufficient response to these acts. The letter is signed by E&C Chair Cathy McMorris Rodgers (R-WA), E&C Subcommittee on Health Chair Brett Guthrie (R-KY), E&C Oversight and Investigations Subcommittee Chair Morgan Griffith (R-VA), E&W Chair Virginia Foxx (R-NC), and E&W Subcommittee on Higher Education and Workforce Development Chair Burgess Owens (R-UT).  KEY LETTER EXCERPTS: “The Gladstone Institutes, an independent biomedical research organization, claims that it takes an active stance against serious issues like discrimination and harassment and aims to ‘ensure all community members at Gladstone feel included’ and that the Institutes will aim to ‘implement accountability measures and reinforce Gladstone’s commitment to having an environment free of harassment.’ However, these values do not seem to be reflected in the actions of leadership in response to recent concerns of antisemitic harassment and discrimination within the Institutes.” [...] “The reports of antisemitic harassment at Gladstone coupled with the inadequate response by leadership is concerning to the Committees. Failing to act decisively to ensure a safe environment for all trainees, faculty, and staff is a grave dereliction of your responsibilities as President of Gladstone.” “Failing to comply with basic safety protections for members of Gladstone or failure to respond appropriately to and prevent harassment and discrimination, no matter the cause, may be grounds to withhold federal funds from the university. Congress has an obligation to exercise oversight of recipients of federal funds when blatant and ongoing Title VI violations appear to be happening. If Congress determines an institution of higher education/research is blatantly ignoring its legal responsibilities, we may consider rescinding research and development funds previously appropriated.” BACKGROUND ON TAXPAYER FUNDING: Gladstone received more than $41 million in funding from the NIH in Fiscal Year 2023, not including potential taxpayer funding that individual faculty may have received through their affiliation with the University of California, San Francisco (UCSF) or any other affiliated universities.   According to the NIH’s Grant Policy Statement, any institution receiving federal funds must assure work environments are free of discriminatory harassment and are safe and conducive to high-quality work.  Institutions receiving federal taxpayer financial assistance—such as NIH grants—are prohibited from discriminating based on a variety of categories, including national origin.   These laws also protect members of the institution who are or are perceived to be members of a group with shared ancestry, such as students/trainees of Jewish heritage. BACKGROUND ON INSTANCES OF ANTISEMITISM : Two days after the October 7, 2023, Hamas terrorist attack, a graduate student working in a lab within Gladstone sent an antisemitic email to all Gladstone faculty, trainees, and staff falsely stating that the attack on innocent Israeli civilians was “the resistance in Gaza launch[ing] a surprise attack against Israel, taking occupation soldiers hostage, taking over Israeli military vehicles, and gain[ing] control over illegal Israeli settlements.”  The email goes on to claim that all casualties resulting from Palestinian actions are the responsibility of Israel.  Immediately following this mass email, members of the Gladstone faculty began contacting the Gladstone Institutes’ President and other leadership, appalled by the language of the email, concerned for their safety and worried that the email could be seen as an incitement to violence.  Jewish members of the Institutes also expressed their deep, personal pain following the Hamas attack, as some members had family or friends reported killed or missing directly after the attack.  These fears—including fears of being attacked in the lab by the author of this cruel and antagonistic email—were shared directly with President Srivastava.  Despite this, Gladstone leadership did not issue a public statement or position against antisemitism to quell fears of Jewish faculty and trainees.  In May 2024, the Center for Combatting Antisemitism sent President Srivastava a letter requesting administrative action to address the hostile environment and disparate treatment of Jewish members at Gladstone.  This letter noted that Gladstone refused to acknowledge Jewish American Heritage Month, Passover, or Holocaust Remembrance Day, despite sending official celebratory emails and holding events for other religious, ethnic, or national holidays, including Black History Month, International Women’s Day, and Ramadan.  The Center followed up with Gladstone several times, but never received a response.  Jewish faculty and trainees have conveyed to leadership within Gladstone instances of antisemitic harassment and discrimination, which faculty and trainees believe were not taken seriously, making some feel uneasy about speaking out.  For example, per a publicly available Fair Employment and Housing Act complaint to the California Civil Rights Division, a Jewish faculty member openly discussed fellow faculty using racial stereotypes, including comments about a “Jewish nose.”  When these comments were brought to human resources, no investigation occurred.  Instead, the complainant was subsequently targeted with an investigation ultimately deemed to be unwarranted.  Then, following the complainant’s post-October 7th advocacy on behalf of Jewish faculty and trainees, the complainant was threatened repeatedly with career-ending termination, allegedly in an attempt to extort a resignation.  When the threats did not have their desired effect, Gladstone placed the complainant on administrative leave and removed the complainant’s electronic access to email and files but also physical access to the complainant’s lab, removing all ability to conduct work on an NIH-funded grant.  Gladstone ultimately paid an undisclosed sum to settle the matter and avoid litigation.  To elevate concerns regarding widespread, ongoing discrimination, Jewish faculty and trainees requested permission to bring in a speaker related to antisemitism.  Other minority groups had previously been given permission to bring in similar anti-racism speakers.  However, while leadership stated it would look into the idea, ultimately no speaker was brought, and no program was launched regarding antisemitism. BACKGROUND ON AFFILIATIONS WITH OTHER INSTITUTIONS UNDER INVESTIGATION : Gladstone Institutes is affiliated with other institutions under congressional investigation.  For example, Gladstone is an affiliate of the UCSF, which is undergoing congressional investigation for reports of antisemitism within the university, medical school, and medical centers.  Most of Gladstone’s principal investigators are also faculty at UCSF, and the Institutes provide research positions and opportunities for graduate students from UCSF.  Moreover, there is a joint institute—the Gladstone-UCSF Institute of Genomic Immunology—further linking the two institutions.  Gladstone is also affiliated with the University of California, Berkeley and Stanford University, both of which are also under investigation for concerns related to antisemitism. CLICK HERE to read the full letter.

Washington, D.C. — In a new letter to Government Accountability Office Comptroller General Gene Dodaro, House Energy and Commerce Committee Republicans have requested an examination of the structure of laboratory safety programs at the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and the National Institutes of Health (NIH).  The letter was signed by Committee Chair Cathy McMorris Rodgers (R-WA), Subcommittee on Health Chair Brett Guthrie (R-KY), and Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA).  KEY LETTER EXCERPT :  This committee remains concerned about the effectiveness of the oversight HHS and its agencies provide to the laboratories they own and operate. In addition to numerous GAO recommendations that remain unimplemented by the FDA, both the CDC and the FDA recently announced organizational reforms to their laboratory safety and security functions, and it is not clear whether these changes will strengthen oversight or create new undue risk. The FDA has, for example, reorganized several of its laboratories such that they now fall within the Office of the Chief Scientist. This raises potential independence concerns, as the FDA’s laboratory safety and security functions report to the same office.  BACKGROUND :  The mission of the U.S. Department of Health and Human Services (HHS) is to enhance the health and well-being of all Americans.   As such, HHS is most directly involved in leading public health preparedness and response efforts, as well as associated research.   However, past safety lapses involving the CDC, the FDA, and the NIH have been the result of multiple breakdowns in compliance with established policies coupled with inadequate oversight.   For example, in July 2014, boxes containing decades-old vials of smallpox and other hazardous biological agents were found in a storage space of an FDA laboratory on the NIH’s campus. GAO and other reviews resulted in numerous findings and recommendations to strengthen laboratory safety and security, which led to changes to the way HHS and its agencies oversee their laboratories.   Likewise, GAO and other reviews have highlighted the importance of laboratory science and security in the handling of federal select agents and other dangerous pathogens in research.  CLICK HERE to read the full letter.

Washington, D.C. — In a letter today to Food and Drug Administration (FDA) Commissioner Robert Califf, M.D., a bipartisan group of House Energy and Commerce Committee Leaders requested a briefing about the presence of counterfeit Ozempic and other semaglutide products in the United States’ medical supply chain.  The letter was signed by Chair Cathy McMorris Rodgers (R-WA) and Ranking Member Frank Pallone, Jr. (D-NJ); Subcommittee on Health Chair Brett Guthrie (R-KY) and Ranking Member Anna G. Eshoo (D-CA); and Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA) and Ranking Member Kathy Castor (D-FL).   KEY LETTER QUOTE : “In addition to concerns about integrity gaps in the legitimate supply chain, we are also concerned about counterfeit Ozempic entering through illegal channels. For example, in June of this year, Eli Lilly issued an open letter expressing concern that counterfeit versions of its own drugs, Mounjaro and Zepbound, were being sold online, through social media and at medical spas. On May 1, 2024, a Department of Justice press release reported that work by FDA’s Office of Criminal Investigations resulted in the arrest of an individual for selling misbranded and adulterated weight loss drugs on TikTok. The Committee fully supports these continued investigations of unlawful sales.”   BACKGROUND :   The FDA alerted the public on December 21, 2023, to the presence of counterfeit Ozempic injection products in the legitimate drug supply; an investigati ve article l ater found that thousands of counterfeit Ozempic pens had arrived in a warehouse in Elmira, New York, as early as the fall of 2023. The fact that counterfeit medications made it into the legitimate medical supply chain raises concern about potential gaps in our supply chain security infrastructure.    This threat continues to grow.   CLICK HERE to read the full letter.

Washington, D.C — In a new letter to Advanced Research Projects Agency for Health (ARPA-H) Director Renee Wegrzyn, the House Committee on Energy and Commerce (E&C) and House Committee on Education and the Workforce (E&W) request information on how ARPA-H is ensuring that institutions and individuals involved in the research projects it funds comply with Title VI to ensure a harassment and discrimination-free environment.  This letter comes after a rise in antisemitism on college and university campuses, including Columbia University and the University of California, San Francisco where ARPA-H currently funds research. It is signed by E&C Chair Cathy McMorris Rodgers (R-WA), E&C Subcommittee on Health Chair Brett Guthrie (R-KY), E&C Oversight and Investigations Subcommittee Chair Morgan Griffith (R-VA), E&W Chair Virginia Foxx (R-NC), and E&W Subcommittee on Higher Education and Workforce Development Chair Burgess Owens (R-UT).  KEY EXCERPT :  “Due to ongoing reports of antisemitism across colleges and universities, federal and congressional investigations into potential civil rights violations at these institutions, and an ongoing congressional investigation into HHS’s and NIH’s handling of these concerns at HHS-funded institutions, the Committees are seeking more information about how ARPA-H ensures that those involved in projects it funds comply with Title VI and relevant civil rights laws to ensure a research environment free of harassment and discrimination, especially towards those of Jewish faith and heritage.”  BACKGROUND :  ARPA-H is an independent agency of the U.S. Department of Health and Human Services (HHS) within the National Institutes of Health (NIH).  ARPA-H reports directly to the Secretary of HHS.  In the last year, ARPA-H has funded more than $595 million in research projects through ISOs and BAA with more than $506 million going to universities and research institutions and the rest to companies or organizations. Some of these research projects include:  August 30, 2024: Up to $39.5 million to Columbia University   August 22, 2024: Up to $7 million to the University of Pennsylvania   August 13, 2024: Up to $18.4 million to the University of Illinois Urbana-Champaign  July 10, 2024: Up to $27 million to the Wyss Institute at Harvard University  June 12, 2024: Up to $24 million to Yale University School of Medicine  April 1, 2024: Up to $35 million to the University of California, San Francisco  September 26, 2023: Up to $104 million to Harvard Medical School  September 25, 2023: Up to $26 million to Stanford University  Of the fourteen university-based projects ARPA-H funded in the last year, eleven (including the eight listed above) are at universities that were recently or are currently under federal and/or congressional investigation for potential Title VI violations and/or are being sued in federal court for permitting antisemitic behavior on campus.  Columbia University has been sued in federal court, is currently undergoing several investigations by the U.S. Department of Education Office for Civil Rights, and is undergoing investigation by congressional committees, for complaints of antisemitism.  The Committee on Energy and Commerce is currently investigating the University of California, San Francisco regarding concerns of antisemitism at the university, medical school, and associated medical centers.  The U.S. Department of Education recently closed its investigation into the University of Illinois-Urbana Champaign with a resolution agreement that found the university was not meeting its obligation under Title VI as it relates to complaints of shared ancestry discrimination—including 135 complaints of anti-Jewish discrimination.  CLICK HERE to read the full letter.

Washington, D.C. — In a new letter to Department of Health and Human Services (HHS) Secretary Xavier Becerra, the House Committee on Energy and Commerce (E&C) and House Committee on Education and the Workforce (E&W) issued a request for documentation related to the Committees’ ongoing investigation into how the department is preventing and responding to antisemitism at grantee institutions. The letter follows up on a May 23, 2024, letter to which HHS failed to respond to adequately and is signed by E&C Chair Cathy McMorris Rodgers (R-WA), E&C Subcommittee on Health Chair Brett Guthrie (R-KY), E&C Oversight and Investigations Subcommittee Chair Morgan Griffith (R-VA), E&W Chair Virginia Foxx (R-NC), and E&W Subcommittee on Higher Education and Workforce Development Chair Burgess Owens (R-UT). KEY EXCERPT :  “Responding on your behalf in an August 22, 2024, letter, the HHS Assistant Secretary for Legislation stated that, “The HHS Office for Civil Right (OCR) enforces federal civil rights laws prohibiting various forms of discrimination in HHS-funded programs and activities […]” and that “OCR takes this duty seriously.” Despite this declaration, the lacking response from HHS failed to provide specific information about how HHS OCR or the NIH have taken steps to ensure that institutions and universities receiving funding from HHS are complying with federal civil rights laws amongst these extensively reported acts of antisemitism, and whether HHS OCR or the NIH have received any complaints regarding potential violations of federal law as it pertains to antisemitism.” The Chairs requested the following documents by no later than October 2, 2024: A list of all misconduct allegations at NIH-funded institutions relating to alleged antisemitic incidents from fiscal year 2023 to present received by HHS OCR and/or the NIH, showing:   the date;   which agency received the allegation;   a brief description of the incident;   role of the alleged perpetrator and victim (e.g., student or faculty) with their names redacted;  institution;   entity responsible for reviewing the case (including whether the complaint is an official Title VI case);   case status;   actions taken by the institution; and   actions taken by HHS/NIH.  All documents and communications, including but not limited to, text messages, emails, and electronic messages, to or from HHS OCR/to or from the NIH referring or related to misconduct allegations or concerns over actions at NIH-funded institutions from fiscal year 2023 to present, referring or relating to, alleged antisemitic incidents; targeting of Jews, Israelis, Zionists, or Zionism; university encampments; and/or the Israeli-Palestinian conflict.  All documents and communication between HHS OCR and other agencies regarding assistance with Title VI compliance, particularly related to antisemitism (shared ancestry).  All documents and communication between HHS OCR and NIH-funded institutions related to Title VI compliance reviews related to antisemitism (shared ancestry).    From fiscal year 2023 to present, all documents, communications, and guidance provided from HHS OCR and the NIH to grantee institutions and individuals at grantee institutions regarding Title VI responsibilities and protections, including those specific to protections for those of Jewish faith and heritage, and all documents or communications regarding HHS/NIH’s stance on antisemitism, the events occurring on university campuses, and/or the Israeli-Palestinian conflict generally.  CLICK HERE to read the full letter.